Corporate Overview
22nd Century Group, Inc. is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants through genetic engineering, gene-editing, and modern plant breeding. Our primary mission in tobacco is to greatly reduce the harm caused by smoking by bringing our reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes – to adult smokers in the U.S. and international markets.
Why Invest

Commercializing disruptive products utilizing advanced alkaloid plant technologies to improve health

VLN® 95% reduced nicotine content cigarettes are the world’s first and only combustible cigarettes to receive Modified Risk Tobacco Product (MRTP) authorization from the FDA

North America’s largest CDMO provider of hemp-derived active ingredients for the pharmaceutical and consumer goods industries
Stock Snapshot
Company Reports
View All SEC FilingsPress Releases
View Press ReleaseLatest Presentation

Investor Presentation
August 2025
Upcoming & Recent Events
View Notice
Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
View NoticeSTIPULATION AND AGREEMENT OF SETTLEMENT
View NoticeCompany
22nd Century Group, Inc.
321 Farmington Road
Mocksville, NC 27028
Investor Relations
Matt Kreps
22nd Century Group
Investor Relations
contact us by phone 214-597-8200
contact us by email
mkreps@xxiicentury.com
Transfer Agent
Continental Stock & Transfer Company
1 State Street, 30th Floor
New York, NY 10004
contact us by phone 212-509-4000
contact us by email
cstmail@continentalstock.com